ERBB2 and neoplasm: At least, only two (50%) of four cases with HER-2 amplification in primary tumours showed HER-2 amplification in micrometastatic cells, and three (75%) of four cases with HER-2 amplification in micrometastatic cells showed HER-2 amplification in the primary tumours.